sr141716 has been researched along with Depressive Disorder in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kreutzkamp, B | 1 |
| Grieb, M; Lutz, B; Moreira, FA | 1 |
| Gorzalka, BB; Hill, MN | 1 |
| Crippa, JA; Moreira, FA | 1 |
| Lachat, C; Lucet, C; Roberfroid, D | 1 |
| Kwatra, SG | 1 |
| Bocquier, A; Bouvenot, G; Bouvenot, J; Cortaredona, S; Jardin, M; Nauleau, S; Sauze, L; Sciortino, V; Verger, P | 1 |
| Buggy, Y; Cornelius, V; Shakir, SA; Wilton, L | 1 |
| Bagdy, G; Gonda, X; Kirilly, E | 1 |
3 review(s) available for sr141716 and Depressive Disorder
| Article | Year |
|---|---|
Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.
Topics: Affect; Animals; Anxiety Disorders; Cannabinoid Receptor Modulators; Depressive Disorder; Dronabinol; Humans; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2009 |
The psychiatric side-effects of rimonabant.
Topics: Anxiety Disorders; Appetite Depressants; Cannabinoid Receptor Modulators; Depressive Disorder; Humans; Metabolic Diseases; Obesity; Piperidines; Placebo Effect; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Smoking; Smoking Cessation | 2009 |
CB1 receptor antagonists: new discoveries leading to new perspectives.
Topics: Anti-Obesity Agents; Anxiety Disorders; Depressive Disorder; Humans; Obesity; Piperidines; Precision Medicine; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2012 |
6 other study(ies) available for sr141716 and Depressive Disorder
| Article | Year |
|---|---|
[Rimonabant. Risk of depression has not been finally clarified].
Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Depressive Disorder; Humans; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Risk | 2008 |
Impairments in endocannabinoid signaling and depressive illness.
Topics: Affect; Anti-Obesity Agents; Antidepressive Agents; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Depression; Depressive Disorder; Endocannabinoids; Humans; Ligands; Obesity; Piperidines; Pyrazoles; Research; Rimonabant; Signal Transduction; Tobacco Use Disorder | 2009 |
Termination of the CRESCENDO trial.
Topics: Anti-Obesity Agents; Cardiovascular Agents; Cardiovascular Diseases; Depressive Disorder; Drug Approval; Europe; Humans; Multicenter Studies as Topic; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Suicide; Treatment Failure | 2010 |
Termination of the CRESCENDO trial.
Topics: Anti-Obesity Agents; Cardiovascular Agents; Cardiovascular Diseases; Cytochrome P-450 CYP2D6; Depressive Disorder; Europe; Humans; Multicenter Studies as Topic; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Research Design; Rimonabant; Suicide; Treatment Failure | 2010 |
Feedback and lessons from the prescription of rimonabant, a drug to be used under strict guidelines, in southeastern France, March 2007 through June 2008.
Topics: Adult; Antidepressive Agents; Body Mass Index; Depressive Disorder; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Prescriptions; Feedback; Female; France; Humans; Insurance, Health, Reimbursement; Logistic Models; Male; Middle Aged; Obesity; Piperidines; Practice Guidelines as Topic; Pyrazoles; Retrospective Studies; Rimonabant | 2011 |
Risk of depressive episodes with rimonabant: a before and after modified prescription event monitoring study conducted in England.
Topics: Adult; Cohort Studies; Depressive Disorder; England; Female; Humans; Male; Middle Aged; Physicians, Primary Care; Piperidines; Prescriptions; Pyrazoles; Rimonabant; Risk Factors | 2011 |